Sentences with phrase «with gliomas»

Dario C. Altieri, M.D., Wistar's President and CEO and lead author of the study, and colleagues showed how the activation of this pathway leads to an unfavorable prognosis for patients with gliomas — a type of brain tumor — and how the pathway could be a valuable therapeutic target in cancer.

«This research is highly significant as it implies that a commercially available drug, amphotericin B, which has never been used before for patients with gliomas, may be a novel treatment to consider in future trials of patients with this frequently lethal cancer,» says Dr. Rutka.

And in May, a week after Massachusetts Sen. Edward Kennedy was diagnosed with a glioma, The EMR Policy Institute, a Marshfield, Vt. — based nonprofit organization that supports research on the effects of electromagnetic radiation, released a statement linking his tumor to heavy cell phone use.

«We then evaluated the system in rats with glioma and found that by using a method called intracranial convection - enhanced delivery, our nanoparticles could penetrate completely throughout the tumor following a single injection,» says Jordan Green, Ph.D, associate professor of biomedical engineering and ophthalmology at Johns Hopkins.

The key to more effective treatment for glioma is to get to grips with the glioma stem cells, which share many characteristics with the normal neural stem cells in the brain.

A pilot study of vaccination with glioma antigen - peptides with Poly - ICLC for children with newly diagnosed malignant brain stem gliomas, non-brainstem high - grade gliomas, recurrent low - grade gliomas or recurrent high grade gliomas (NCT01130077).

A pilot study of vaccination with glioma antigen - peptides with Poly - ICLC for children with newly diagnosed malignant brain stem gliomas, non-brainstem high - grade gliomas, recurrent low - grade gliomas or recurrent high grade gliomas -LRB-

Not exact matches

Frustrated with the lack of investment in research and drug development devoted to pediatric brain tumor gliomas, the Kamens decided to take action and launch their foundation.

In December 2017, writing in Computer Methods in Applied Mechanics and Engineering, Yankeelov and collaborators at UT Austin and Technical University of Munich, showed that they can predict how brain tumors (gliomas) will grow and respond to X-ray radiation therapy with much greater accuracy than previous models.

The study, published online April 16 in Nature Medicine, represents the first time a severe brainstem cancer, diffuse intrinsic pontine glioma, has been eradicated in mice with the tumor.

For this study, Nakano and his collaborators used cancer cells from 40 patients with high - grade gliomas, focusing on tumor cells with a stem - cell signature.

Inhibiting ALDH1A3 - mediated pathways slows the growth of mesenchymal glioma stem cells and might provide a promising therapeutic approach for glioblastomas with a mesenchymal signature.

The investigators identified evidence of HRD - related mutations in 11.61 percent of them, with the highest concentration of mutations in endometrial cancer, gliomas, and ovarian cancers (38, 15 and 12 percent respectively).

When combined with the compound, called ganciclovir, these loaded nanoparticles were 100 percent effective at killing glioma cells grown in laboratory dishes.

Despite improvements in the past few decades with surgery, chemotherapy and radiation therapy, a predictably curative treatment for glioma does not yet exist.

The eight - gene signature was also compatible for people with lower grade glioma.

In addition to revealing that biodegradable polymeric nanoparticles represent a promising mode of gene delivery for glioma, the findings show that nonviral DNA delivery of HSVtk combined with administration of ganciclovir has potent antitumor effects.

With an annual incidence of approximately five cases per 100,000 persons, gliomas are the most frequently occurring brain tumor in adults.

The three molecular super clusters of lower grade gliomas have either: • Wild - type IDHI1 and IDH2 with no mutations.

Prior studies have shown that levels of miR - 184 are unusually low in tissue samples from patients with malignant gliomas.

More activity of the neuroligin - 3 gene in high - grade gliomas was linked to shorter survival among patients with these tumors.

Studies are underway, and similar to the glioma therapy development, I am working to develop clinical trials for brain metastasis, together with medical oncologists Mansoor Saleh, M.D., Andres Forero, M.D., and others at UAB.»

In clinical samples of high - grade gliomas from patients, the expression levels of both FOXD1 and ALDH1A3 were inversely correlated with disease progression — gliomas with high levels were more rapidly fatal than were gliomas with low levels.

Deadly brain tumors called high - grade gliomas grow with the help of nerve activity in the cerebral cortex, according to a new study by researchers at the Stanford University School of Medicine.

New research out of the University of Michigan supports combining two approaches to fight back against gliomas: attacking the tumor with gene therapy while enhancing the immune system's ability to fight it, too.

In collaboration with colleagues in the United States, Lene Uhrbom's research group has studied glioma development in mice.

Researchers investigating pediatric low - grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood cancer.

They currently have a trial under way at the U-M Health System which tests a two - part gene therapy approach in patients with brain tumors called gliomas in an effort to get the immune system to attack the tumor.

«Areas of glioblastoma tumors correlate with separate subtypes of glioma stem cells.»

The activation of this signaling pathway progressively increased in different types of gliomas, with the highest activity seen in patients with glioblastoma, a particularly difficult - to - treat form of brain cancer that represents approximately 15 percent of all brain tumors.

They will follow this approach to design a novel treatment plan by rationally combining gemcitabine with cell cycle checkpoint inhibitor, oxygen - enrich gas inhalation, and radiotherapy to significantly inhibit the growth of aggressive glioma.

«The treatment with gemcitabine and MK - 8776 to inhibit glioma growth is a promising strategy that warrants further investigation,» said Khan.

Reykjavik, ICELAND, 25 September 2011 — Scientists at deCODE Genetics and academic collaborators from Iceland, The Netherlands, Spain, Denmark, Germany, Sweden, the USA, the UK and Romania today report the discovery of a variant in the sequence of the human genome associated with risk of developing basal cell carcinoma of the skin (BCC), as well as prostate cancer and glioma, the most serious form of brain cancer.

Human glioma cells expressing human CD4, infected with an amphotropic retrovirus encoding the cDNA of the CD4 message.

Professor Ferner's research with national and international collaborators focuses on defining clinical phenotype in the neurofibromatoses, determining the natural history of optic pathway glioma and developing robust clinical and patient centred outcome measures for monitoring novel therapies.

In some cases, for example with a type of brain tumors called gliomas, it is not even known yet.

With - No - Lysine Kinase 3 (WNK3) stimulates glioma invasion by regulating cell volume.

We've linked up with UCL on this, and together have the patient numbers to increase the number and different subtypes and different types of glioma we can include in this open library.

Also this week, members of the St. Jude Children's Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) described the whole - genome sequencing pediatric diffuse intrinsic pontine glioma (DIPG), 7 cases with tumor and matched germline DNA.

St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project offers new leads to improved outcomes for children with high - grade glioma brain tumors; particularly youngest patients

Pediatric Cancer Genome Project researchers found that ACVR1 was mutated in 32 percent of 57 patients diagnosed with a subtype of HGG called diffuse intrinsic pontine glioma (DIPG).

A phase I trial of the H3.3K27M - specific peptide vaccine combined with poly - ICLC for newly diagnosed H3.3K27M - positive diffuse intrinsic pontine glioma (DIPG) and other newly diagnosed H3.3K27M - positive gliomas (NCT02960230).

A phase 1 trial of a dendritic cell (DC) vaccine administered with imiquimod, a TLR7 agonist that stimulates the innate immune system, for patients with malignant glioma and glioblastoma (NCT01808820).

Cancer incidence in families with multiple glioma patients.

A phase I trial of the H3.3K27M - specific peptide vaccine combined with poly - ICLC for newly diagnosed H3.3K27M - positive diffuse intrinsic pontine glioma (DIPG) and other newly diagnosed H3.3K27M - positive gliomas -LRB-

Newly diagnosed supratentorial brain lesion compatible with a high grade glioma by MR (magnetic resonance) with no prior treatment with either gene therapy, chemotherapy or radiation treatments that is amenable to attempted gross total resection (GTR).

Despite the marginal improvements in survival of patients suffering from malignant glioma treated with gene therapy vectors, the clinical trials conducted so far using viral vectors, in particular adenoviral vectors, have proven that the use of adenoviral vectors is a safe therapeutic approach, even in large, multicenter, phase 3 clinical trials.

Gliomas are deadly brain cancers whose progression is strongly associated with overexpression of the RNA - binding regulatory protein HuR.

Johns Hopkins scientists are conducting research in high - grade glioma patients to measure the blood levels of cytomegalovirus (CMV), a common virus that can cause severe disease in patients with weakened immune systems.

On their surface, the liposomes are studded with proteins that target receptors on glioma cells.